The latest price target for Esperion Therapeutics (NASDAQ:ESPR) was reported by HC Wainwright & Co. on January 10, 2025. The analyst firm set a price target for $0.00 expecting ESPR to fall to within 12 months (a possible -100.00% downside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Esperion Therapeutics (NASDAQ:ESPR) was provided by HC Wainwright & Co., and Esperion Therapeutics reiterated their buy rating.

The last upgrade for Esperion Therapeutics Inc happened on June 15, 2023 when B of A Securities raised their price target to $4. B of A Securities previously had an underperform for Esperion Therapeutics Inc.

The last downgrade for Esperion Therapeutics Inc happened on June 20, 2024 when B of A Securities changed their price target from $2.9 to $2.5 for Esperion Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on January 10, 2025 so you should expect the next rating to be made available sometime around January 10, 2026.

While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a reiterated with a price target of $0.00 to $0.00. The current price Esperion Therapeutics (ESPR) is trading at is $2.15, which is out of the analyst’s predicted range.